1-4 of 4
Daniel H. Albert, PhD
Close
Sort by
Journal Articles

The Synergistic Effect of Venetoclax Combined with a CDK9 Inhibitor in Primary Diffuse Large B Cell Lymphoma and Follicular Lymphoma Cells

Xiaoxian Zhao, PhD, Darren C. Phillips, PhD, Andrew J. Souers, PhD, Juraj Bodo, PhD, Paul Tapang, Daniel H Albert, PhD, Lisa Durkin, Eric D. Hsi, MD
Journal: Blood
Blood (2015) 126 (23): 2746.
https://doi.org/10.1182/blood.V126.23.2746.2746
Published: 2015
Journal Articles

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

Jun Chen, MDPhD, Sha Jin, MS, Paul Tapang, Stephen K Tahir, PhD, Morey Smith, John Xue, Haichao Zhang, PhD, Wenqing Gao, PhD, Yunsong Tong, PhD, Richard Clark, Justin L. Ricker, MD PhD, Thomas D Penning, PhD, Daniel H Albert, PhD, Darren C Phillips, PhD, Andrew J Souers, PhD, Joel D. Leverson, PhD
Journal: Blood
Blood (2014) 124 (21): 2161.
https://doi.org/10.1182/blood.V124.21.2161.2161
Published: 2014
Journal Articles

Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.

Guillermo Garcia-Manero, MD, Raoul Tibes, MD, Yi-Lin Chiu, PhD, Hao Xiong, PhD, Qin Qin, Peter Ansell, PhD, Daniel H. Albert, PhD, BSc, Chris Tse, PhD, Brian Oliver, Karim Sajwani, MS, Mark D. McKee, MD, Justin L. Ricker, MD, PhD, H. Jean Khoury, MD
Journal: Blood
Blood (2012) 120 (21): 2617.
https://doi.org/10.1182/blood.V120.21.2617.2617
Published: 2012
Journal Articles

Multi-Targeted Receptor Tyrosine Kinase Inhibitor, ABT-869, Induces Apoptosis and Inhibition of Proliferation of Ba/F3 FLT-3 ITD Mutant Cells.

Jenny E. Hernandez, BS, Junling Li, Ru-Qi Wei, Paul Tapang, Steven K. Davidsen, PhD, Daniel H. Albert, PhD, Patrick A. Marcotte, PhD, Keith B. Glaser, PhD, Cecilia Fu, M.D., Kathleen M. Sakamoto, M.D. PhD.
Journal: Blood
Blood (2007) 110 (11): 1589.
https://doi.org/10.1182/blood.V110.11.1589.1589
Published: 2007